Comparative Pharmacology
Head-to-head clinical analysis: BOSENTAN versus FILSPARI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BOSENTAN versus FILSPARI.
BOSENTAN vs FILSPARI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Endothelin receptor antagonist; blocks endothelin-1 (ET-1) from binding to ETA and ETB receptors, inhibiting vasoconstriction and proliferation.
FILSPARI (sparsentan) is an endothelin receptor antagonist (ERA) and angiotensin II receptor blocker (ARB) with high affinity for the endothelin type A (ETA) receptor and angiotensin II type 1 (AT1) receptor. It reduces proteinuria in IgA nephropathy by inhibiting endothelin-1 mediated vasoconstriction, inflammation, and fibrosis, and by blocking angiotensin II mediated effects.
62.5 mg orally twice daily for 4 weeks, then increase to maintenance dose of 125 mg twice daily.
200 mg orally once daily, with or without food.
None Documented
None Documented
Clinical Note
moderateBosentan + Digoxin
"The serum concentration of Digoxin can be decreased when it is combined with Bosentan."
Clinical Note
moderateBosentan + Digitoxin
"The serum concentration of Digitoxin can be decreased when it is combined with Bosentan."
Clinical Note
moderateBosentan + Torasemide
"Bosentan may increase the hypotensive activities of Torasemide."
Clinical Note
moderateBosentan + Estrone sulfate
Terminal elimination half-life is approximately 5 hours in healthy adults, but prolonged in patients with hepatic impairment (up to 21 hours in Child-Pugh Class A and B).
Terminal half-life ~30 hours in healthy subjects, supporting once-daily dosing.
Primarily biliary excretion (≥50% as unchanged drug) with fecal elimination; renal excretion accounts for <3% of unchanged drug.
Primarily hepatic metabolism; <1% excreted unchanged in urine. ~59% of dose recovered in feces and ~27% in urine as metabolites.
Category D/X
Category C
Endothelin Receptor Antagonist
Endothelin Receptor Antagonist / ARB
"The serum concentration of Estrone sulfate can be decreased when it is combined with Bosentan."